FULCRUM THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.14 USD | +0.14% |
|
+4.39% | +5.78% |
| Mar. 18 | Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer | MT |
| Mar. 18 | Fulcrum Therapeutics, Inc. Announces Executive Changes | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 375.4 | 319.5 | 717 | 378.9 | 417.3 | 443.8 | - | - |
| Enterprise Value (EV) 1 | 278.7 | 206.6 | 498.8 | 176 | 181.1 | 385.1 | 562.4 | 843.5 |
| P/E ratio | -2.05 x | -4.2 x | -7.72 x | -2.98 x | -4.25 x | -4.15 x | -4.34 x | -7.41 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 36.2 x | 37.4 x | 59.7 x | 149 x | 265 x | 38 x | 9.12 x |
| EV / Revenue | - | 23.4 x | 26 x | 27.8 x | 64.6 x | 230 x | 48.2 x | 17.3 x |
| EV / EBITDA | -3.39 x | -2.98 x | -6.35 x | -1.6 x | -1.67 x | -3.06 x | -4.18 x | -5.71 x |
| EV / FCF | - | -3.76 x | -6.22 x | -1.78 x | -1.98 x | -3.84 x | -5.69 x | -11 x |
| FCF Yield | - | -26.6% | -16.1% | -56.3% | -50.5% | -26.1% | -17.6% | -9.09% |
| Price to Book | 4.33 x | 3.45 x | 3.4 x | 1.91 x | - | - | - | - |
| Nbr of stocks (in thousands) | 22,558 | 27,281 | 40,529 | 52,051 | 61,823 | 62,154 | - | - |
| Reference price 2 | 16.64 | 11.71 | 17.69 | 7.280 | 6.750 | 7.140 | 7.140 | 7.140 |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/9/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 8.823 | 19.16 | 6.342 | 2.805 | 1.678 | 11.67 | 48.67 |
| EBITDA 1 | -82.16 | -69.23 | -78.54 | -109.7 | -108.5 | -126 | -134.5 | -147.8 |
| EBIT 1 | -84.22 | -71.61 | -81.05 | -112.1 | -110.7 | -124.2 | -126.9 | -102.1 |
| Operating Margin | - | -811.64% | -422.97% | -1,768.12% | -3,945.24% | -7,404.27% | -1,087.59% | -209.88% |
| Earnings before Tax (EBT) 1 | -82.68 | -70.82 | -80.85 | -109.9 | -97.34 | -116.2 | -124.9 | -91.33 |
| Net income 1 | -82.68 | -70.82 | -80.85 | -109.9 | -97.34 | -113.3 | -116.7 | -98.38 |
| Net margin | - | -802.66% | -421.89% | -1,732.43% | -3,470.05% | -6,753.93% | -1,000.44% | -202.15% |
| EPS 2 | -8.130 | -2.790 | -2.290 | -2.440 | -1.590 | -1.720 | -1.644 | -0.9633 |
| Free Cash Flow 1 | - | -55 | -80.19 | -99.01 | -91.47 | -100.4 | -98.83 | -76.65 |
| FCF margin | - | -623.34% | -418.47% | -1,561.23% | -3,261.07% | -5,983.43% | -846.98% | -157.48% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/9/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.935 | 5.058 | 2.592 | 1.882 | 1.183 | 0.685 | 0.295 | 0.88 | 0.759 | 0.871 | 0.3601 | 0.3717 | 0.448 | 0.3969 | - |
| EBITDA | -20.15 | -22.94 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.77 | -23.56 | -26 | -34.24 | -23.89 | -28.01 | -27.94 | -27.29 | -27.44 | -27.99 | -29.58 | -30.45 | -31.21 | -32.09 | -36.5 |
| Operating Margin | -420.87% | -465.78% | -1,003.01% | -1,819.08% | -2,019.44% | -4,089.2% | -9,471.19% | -3,101.36% | -3,615.28% | -3,213.78% | -8,213.43% | -8,193.03% | -6,967.34% | -8,085.01% | - |
| Earnings before Tax (EBT) 1 | -20.72 | -23.48 | -25.93 | -34.07 | -23.74 | -26.14 | -24.78 | -23.78 | -24.02 | -24.76 | -27.26 | -28.57 | -29.49 | -30.87 | -35.05 |
| Net income 1 | -20.72 | -23.48 | -25.93 | -34.07 | -23.74 | -26.14 | -24.78 | -23.78 | -24.02 | -24.76 | -27.13 | -27.89 | -28.48 | -29.37 | -35.05 |
| Net margin | -419.78% | -464.29% | -1,000.31% | -1,810.31% | -2,006.59% | -3,815.33% | -8,399.66% | -2,702.61% | -3,164.3% | -2,842.25% | -7,534.48% | -7,503.61% | -6,356.62% | -7,400.47% | - |
| EPS 2 | -0.5700 | -0.5800 | -0.6400 | -0.8300 | -0.5100 | -0.5000 | -0.4100 | -0.3800 | -0.3900 | -0.4000 | -0.4333 | -0.4300 | -0.4367 | -0.4400 | -0.5500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/3/22 | 5/9/22 | 8/11/22 | 11/8/22 | 3/9/23 | 5/15/23 | 8/3/23 | 11/7/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 119 | 400 |
| Net Cash position 1 | 96.7 | 113 | 218 | 203 | 236 | 58.7 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.8819 x | -2.704 x |
| Free Cash Flow 1 | - | -55 | -80.2 | -99 | -91.5 | -100 | -98.8 | -76.6 |
| ROE (net income / shareholders' equity) | -94.9% | -77.7% | -52.7% | -53.5% | -44.8% | -99.8% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 3.850 | 3.390 | 5.210 | 3.820 | - | - | - | - |
| Cash Flow per Share 2 | -3.570 | -2.120 | -2.220 | -2.160 | -1.480 | -1.310 | -1.210 | - |
| Capex 1 | - | 1.34 | 1.71 | 1.96 | 0.51 | 1.43 | 1.15 | 1.56 |
| Capex / Sales | - | 15.21% | 8.94% | 30.95% | 18.11% | 85.08% | 9.82% | 3.21% |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/9/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
7.14
USD
Average target price
13.25
USD
Spread / Average Target
+85.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.78% | 444M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- FULC Stock
- Financials Fulcrum Therapeutics, Inc.
